April 18, 2018
Cambridge, MA

Letter to the Duchenne Community: Update on IGNITE DMD Clinical Trial

Letter to the Duchenne Community: Update on IGNITE DMD Clinical Trial

 

Dear Duchenne Community Members,

 

As valued partners in the fight against Duchenne muscular dystrophy (DMD), we wanted to share with you an update on our ongoing interactions with the U.S. Food and Drug Administration (FDA) on IGNITE DMD, our Phase I/II clinical trial to assess the safety and efficacy of SGT-001 in patients with DMD. We also shared this update in a press release that can be found here.

As you know, we recently announced that the FDA put IGNITE DMD on full clinical hold due to a serious adverse event (SAE) experienced by the first patient dosed with SGT-001. We reported the event to the FDA and have recently received the formal clinical hold letter, which outlined the agency’s additional information requests. We are working tirelessly to develop a comprehensive plan to address these questions and are committed to maintaining dialogue with the FDA with the hope of resuming IGNITE DMD as soon as possible. Most importantly, we’re pleased to say the treating physician has reported the patient is doing well.

As part of our update, we are also happy to share that we have been able to successfully resolve the previously-announced partial clinical hold on the planned high dose of SGT-001 in IGNITE DMD, which was due to manufacturing-related questions from the FDA. While encouraging, IGNITE DMD remains on hold until we address the full clinical hold as mentioned above.

Solid is deeply committed to advancing our mission to solve DMD. Our goal is and always has been to bring forward only the programs that we believe have life-changing potential and develop a portfolio of treatments to benefit all patients, regardless of their underlying genetic mutation, age or stage of disease. We knew this wasn’t going to be easy, but our mission and the possibility of helping those affected by this cruel disease guide every decision we make and project we take on. 

We appreciate the Duchenne community’s continued support. We will provide additional updates in the future.

 

Sincerely,

The Solid Team

Related news

Sep07

The Solid Biosciences team was honored to join the Duchenne muscular dystrophy community in recognizing World Duchenne Awareness Day.

Only together can we end this devastating disease.

Jun18

We’re pleased to share with you that the FDA has lifted the clinical hold on IGNITE DMD.

Mar14

Today we announced that the U.S. Food and Drug Administration has placed our Phase I/II clinical trial for SGT-001, IGNITE DMD, on Clinical Hold following a serious adverse event that occurred in the first patient dosed, a non-ambulatory adolescent.

Feb28

Solid Biosciences is proud to join the global rare disease community again this year to observe Rare Disease Day

Nov30

Today we are excited to announce the initiation of our first clinical trial for SGT-001.

Jun08

We are getting ready to initiate a clinical study for our gene transfer candidate, SGT-001, later this year.

Jun08

Solid Biosciences is pleased to announce additional research grant from our Australia-based partner Save Our Sons and an initial research grant from Ireland-based Join Our Boys.

Jan30

The Duchenne Research Fund (DRF) provided Solid with a research grant of $600,000 to support its LTBP4 program to combat fibrosis and to support novel biomarker work in Duchenne muscular dystrophy (DMD).

Oct14

It has been an exciting and emotional time for our Duchenne muscular dystrophy (DMD) community.

Sep15

Solid was proud to sponsor the 8th Annual Gals For Cal team at the recent Max Performance Title 9 Triathlon at Hopkinton State Park in Massachusetts.

Pages

More information about Solid?

Please subscribe to receive our latest news